Novavax licenses VLP vaccine technology to LGLS

Under the pact, Novavax will provide VLP technology transfer and manufacturing support for LGLS’s new vaccine production facility.

As per the agreement, LGLS will be manufacture, develop and commercialize influenza vaccines using Novavax’s recombinant VLP technology in South Korea.

The tie up allows Novavax to get upfront and milestone payment and from LGLS in addition to double-digit royalty rate payments from commercial sales.

However, LGLS has taken responsibility to fund clinical development and licensure of influenza VLP vaccines in South Korea and other countries, and for construction of a new VLP vaccine manufacturing facility planned at LGLS’s Osong campus in South Korea.